Company Encyclopedia
View More
name
KONTA CHINA
01312.HK
Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediate in Mainland China, Singapore, Taiwan, and internationally. It operates through Pharmaceutical Business and Fitness Business segments. The company offers prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and health activities. It also offers corporate advisory services; and researches and develops medical products.
1.450 T
01312.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking37/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-41.48%E
    • Profit Margin-40.68%E
    • Gross Margin56.24%B
  • Growth ScoreD
    • Revenue YoY6.55%C
    • Net Profit YoY-473.67%E
    • Total Assets YoY-31.85%E
    • Net Assets YoY-41.46%E
  • Cash ScoreC
    • Cash Flow Margin-245.81%D
    • OCF YoY6.55%C
  • Operating ScoreB
    • Turnover0.63B
  • Debt ScoreC
    • Gearing Ratio46.15%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Vice President of KONTA CHINA Resigns

    KONTA CHINA announced that Qiaolina has submitted her resignation as the company's executive director and vice president due to other work commitments, effective from November 14

    AASTOCKS·
    HK
    01312
    0.00%
    AASTOCKS·
    HK
    01312
    0.00%

    KONTA CHINA: Its Taiwan affiliate company Quanzhen Concept may be liquidated

    KONTA CHINA announced that its indirectly held 29% joint venture, QuanZhen Concept, will cease operations starting from October 1, 2025, and may face liquidation. The total debt of QuanZhen Concept is approximately NT$3.001 billion (about HKD 771 million). Despite the potential liquidation, it is expected that there will be no significant impact on the overall financial condition of the group and the pharmaceutical division's business. The company will continue to monitor the fitness business and the liquidation process of QuanZhen Concept

    AASTOCKS·
    HK
    01312
    0.00%
    AASTOCKS·
    HK
    01312
    0.00%

    KONTA CHINA released its interim results, with a loss attributable to shareholders of HKD 282 million, turning from profit to loss year-on-year

    KONTA CHINA released its interim results for the period ending June 30, 2025, with revenue of HKD 453 million, a year-on-year decrease of 1.3%. The company's loss attributable to shareholders was HKD 282 million, compared to a profit of HKD 4.745 million in the same period last year. The basic loss per share was HKD 5.06 cents. The loss was mainly due to poor performance in the fitness business franchise, an uncertain economic outlook, and intensified competition, leading to credit losses and impairment of intangible assets

    Zhitong·
    HK
    01312
    0.00%
    Zhitong·
    HK
    01312
    0.00%

    KONTA CHINA awarded the construction contract for the Beijing R&D complex project, involving RMB 33.67 million

    KONTA CHINA announced that its wholly-owned subsidiary Tongfang Pharmaceutical signed a construction contract with Beijing Qingkong on August 18, appointing it as the general contractor for the Beijing R&D Complex project. The contract amount is RMB 33.6724 million, with a contract period of 320 days. The project includes foundation, main structure, decoration, etc., and is expected to complete a five-story building primarily for R&D purposes. Since Beijing Qingkong is an indirectly non-wholly-owned subsidiary of the controlling shareholder of KONTA CHINA, this transaction constitutes a related party transaction

    AASTOCKS·
    HK
    01312
    0.00%
    AASTOCKS·
    HK
    01312
    0.00%

    "Profit Warning" KONTA CHINA expects half-year losses to expand to at least 283 million yuan

    KONTA CHINA issued a profit warning, expecting a net loss of between 283 million and 346 million yuan for the six months ending in June, compared to a profit of 4.5 million yuan in the same period last year. The increase in losses is mainly due to the expected impact of impairment losses, compounded by a decline in revenue and gross profit in the pharmaceutical division due to intensified market competition

    AASTOCKS·
    HK
    01312
    0.00%
    AASTOCKS·
    HK
    01312
    0.00%
    © 2025 Longbridge｜Disclaimer